论文部分内容阅读
目的:探讨西宁地区妊娠期高血压疾病孕妇凝血功能的改变,提出临床治疗对策。方法:选取久居于西宁地区的妊娠期高血压疾病孕妇60例,分为研究组Ⅰ30例(轻度子痫前期),研究组Ⅱ30例(重度子痫前期)及随机选取同期住院分娩的健康孕妇22例为对照组。抽取静脉血检测血浆凝血酶原时间(PT)、活化的部分凝血活酶时间(APTT)、纤维蛋白原(Fib)、凝血酶时间(TT)、凝血酶原时间国际标准化比值(INR)、纤维蛋白原降解产物(FDP)、D-二聚体、血小板计数、红细胞压积等指标,并对其进行统计学分析。结果:正常孕妇与妊娠期高血压疾病患者血凝指标比较,研究组Ⅱ与正常组比较,TT有显著增加,血小板有显著减少,P<0.05,有统计学意义;PT、APTT、Fib、INR、FDP D-二聚体均无明显差异,无统计学意义;研究组Ⅱ与研究组Ⅰ比较、研究组Ⅰ与正常组比较均无统计学意义。结论:西宁地区重度子痫前期的孕妇血凝及血小板检测结果与正常孕妇相比有明显差异,临床可根据此差异性对重度子痫前期孕妇的病情进行评估,并应严格监测血凝及血小板的变化,以及时跟踪病情进展,为临床合理制定应对措施从而改善母儿结局,提出客观的临床参考依据。
Objective: To investigate the change of coagulation function of pregnant women with hypertensive disorder of pregnancy in Xining area and to put forward the clinical treatment countermeasures. Methods: A total of 60 pregnant women with gestational hypertension were enrolled in this study. They were divided into study group (130 cases) (mild preeclampsia), study group (Ⅱ): 30 cases (severe preeclampsia) and healthy pregnant women hospitalized in the same period 22 cases as control group. Venous blood samples were collected for determination of plasma prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fib), thrombin time (TT), international normalized ratio of prothrombin time (INR) Protein degradation products (FDP), D-dimer, platelet count, hematocrit and other indicators, and its statistical analysis. Results: Compared with the normal group, the serum levels of TT in normal pregnant women and normal pregnant women were significantly increased (P <0.05), while the levels of TT, PT, APTT, Fib and INR were significantly decreased , FDP D-dimer no significant difference, no statistical significance; study group Ⅱ and study group Ⅰ, study group Ⅰ and normal group were not statistically significant. Conclusion: The results of hemagglutination and platelet test in pregnant women with severe preeclampsia in Xining have significant difference compared with normal pregnant women. According to the difference, the condition of pregnant women with severe preeclampsia can be assessed according to the difference, and the blood coagulation and platelet Of the changes in order to track the progress of the disease in time for the clinical development of appropriate response measures to improve maternal and child outcomes, put forward objective clinical reference.